Diamyd Medical AB (publ)
Diamyd Medical AB (publ) develops precision medicine therapies for the treatment of autoimmune diabetes. The company develops Diamyd, an antigen-specific immunotherapy, which is in phase III clinical trial for the treatment of type 1 diabetes and latent autoimmune diabetes in adults (LADA); and Remygen, an immunomodulation therapy, that is in phase I/II clinical trial for the treatment of with ty… Read more
Diamyd Medical AB (publ) (DMYD-B) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of November 2025: -0.189x
Based on the latest financial reports, Diamyd Medical AB (publ) (DMYD-B) has a cash flow conversion efficiency ratio of -0.189x as of November 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-43.70 Million) by net assets (Skr231.63 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Diamyd Medical AB (publ) - Cash Flow Conversion Efficiency Trend (2010–2025)
This chart illustrates how Diamyd Medical AB (publ)'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Diamyd Medical AB (publ) Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Diamyd Medical AB (publ) ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
PROTALIX BIOTHERAP.DL-01
F:PBDA
|
N/A |
|
Hes Technology Group
SHE:002963
|
0.053x |
|
PowerCell Sweden AB (publ)
PINK:PCELF
|
0.016x |
|
Linc AB
ST:LINC
|
0.003x |
|
Elicio Therapeutics Inc.
NASDAQ:ELTX
|
-2.905x |
|
Benchmark Metals Inc
V:CEI
|
0.029x |
|
CAMP4 THERAPEUTICS CORPORATION
NASDAQ:CAMP
|
0.132x |
|
Jiangsu Teeyer Intelligent Equipment Co.,Ltd.
SHG:603273
|
-0.011x |
Annual Cash Flow Conversion Efficiency for Diamyd Medical AB (publ) (2010–2025)
The table below shows the annual cash flow conversion efficiency of Diamyd Medical AB (publ) from 2010 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-08-31 | Skr280.00 Million | Skr-169.68 Million | -0.606x | +31.55% |
| 2024-08-31 | Skr145.92 Million | Skr-129.18 Million | -0.885x | -35.15% |
| 2023-08-31 | Skr169.40 Million | Skr-110.96 Million | -0.655x | -50.64% |
| 2022-08-31 | Skr214.38 Million | Skr-93.22 Million | -0.435x | +24.82% |
| 2021-08-31 | Skr189.26 Million | Skr-109.47 Million | -0.578x | -348.38% |
| 2020-08-31 | Skr72.49 Million | Skr16.88 Million | 0.233x | +137.31% |
| 2019-08-31 | Skr62.78 Million | Skr-39.19 Million | -0.624x | +35.41% |
| 2018-08-31 | Skr43.01 Million | Skr-41.56 Million | -0.966x | -224.51% |
| 2017-08-31 | Skr86.67 Million | Skr-25.81 Million | -0.298x | +50.91% |
| 2016-08-31 | Skr29.26 Million | Skr-17.75 Million | -0.607x | -30.94% |
| 2015-08-31 | Skr39.52 Million | Skr-18.31 Million | -0.463x | -22.60% |
| 2014-08-31 | Skr44.16 Million | Skr-16.69 Million | -0.378x | -66.13% |
| 2013-08-31 | Skr60.29 Million | Skr-13.71 Million | -0.227x | -66.41% |
| 2012-08-31 | Skr409.58 Million | Skr-55.99 Million | -0.137x | +32.98% |
| 2011-08-31 | Skr460.97 Million | Skr-94.03 Million | -0.204x | -128.44% |
| 2010-08-31 | Skr314.78 Million | Skr225.77 Million | 0.717x | -- |